{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:46:21Z","timestamp":1785584781252,"version":"3.56.0"},"reference-count":38,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:00:00Z","timestamp":1693008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20dm0107071"],"award-info":[{"award-number":["JP20dm0107071"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["22ym0126095h0001"],"award-info":[{"award-number":["22ym0126095h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["22K06644"],"award-info":[{"award-number":["22K06644"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan AMED","doi-asserted-by":"publisher","award":["JP20dm0107071"],"award-info":[{"award-number":["JP20dm0107071"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan AMED","doi-asserted-by":"publisher","award":["22ym0126095h0001"],"award-info":[{"award-number":["22ym0126095h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan AMED","doi-asserted-by":"publisher","award":["22K06644"],"award-info":[{"award-number":["22K06644"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20dm0107071"],"award-info":[{"award-number":["JP20dm0107071"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22ym0126095h0001"],"award-info":[{"award-number":["22ym0126095h0001"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K06644"],"award-info":[{"award-number":["22K06644"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Takeda Science Foundation","award":["JP20dm0107071"],"award-info":[{"award-number":["JP20dm0107071"]}]},{"name":"Takeda Science Foundation","award":["22ym0126095h0001"],"award-info":[{"award-number":["22ym0126095h0001"]}]},{"name":"Takeda Science Foundation","award":["22K06644"],"award-info":[{"award-number":["22K06644"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>An increase in the global aging population is leading to an increase in age-related conditions such as dementia and movement disorders, including Alzheimer\u2019s disease (AD), Parkinson\u2019s disease (PD), and dementia with Lewy bodies (DLB). The accurate prediction of risk factors associated with these disorders is crucial for early diagnosis and prevention. Biomarkers play a significant role in diagnosing and monitoring diseases. In neurodegenerative disorders like \u03b1-synucleinopathies, specific biomarkers can indicate the presence and progression of disease. We previously demonstrated the pathogenic impact of fatty acid-binding proteins (FABPs) in \u03b1-synucleinopathies. Therefore, this study investigated FABPs as potential biomarkers for Lewy body diseases. Plasma FABP levels were measured in patients with AD, PD, DLB, and mild cognitive impairment (MCI) and healthy controls. Plasma FABP3 was increased in all groups, while the levels of FABP5 and FABP7 tended to decrease in the AD group. Additionally, FABP2 levels were elevated in PD. A correlation analysis showed that higher FABP3 levels were associated with decreased cognitive function. The plasma concentrations of Tau, GFAP, NF-L, and UCHL1 correlated with cognitive decline. A scoring method was applied to discriminate between diseases, demonstrating high accuracy in distinguishing MCI vs. CN, AD vs. DLB, PD vs. DLB, and AD vs. PD. The study suggests that FABPs could serve as potential biomarkers for Lewy body diseases and aid in early disease detection and differentiation.<\/jats:p>","DOI":"10.3390\/ijms241713267","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T01:56:57Z","timestamp":1693187817000},"page":"13267","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Using Fatty Acid-Binding Proteins as Potential Biomarkers to Discriminate between Parkinson\u2019s Disease and Dementia with Lewy Bodies: Exploration of a Novel Technique"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5916-7847","authenticated-orcid":false,"given":"Ichiro","family":"Kawahata","sequence":"first","affiliation":[{"name":"Department of CNS Drug Innovation, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Sekimori","sequence":"additional","affiliation":[{"name":"Department of CNS Drug Innovation, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Oizumi","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Hospital Organization Sendai Nishitaga Hospital, Sendai 982-0805, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-2486","authenticated-orcid":false,"given":"Atsushi","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Hospital Organization Sendai Nishitaga Hospital, Sendai 982-0805, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohji","family":"Fukunaga","sequence":"additional","affiliation":[{"name":"Department of CNS Drug Innovation, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1750-3639.2009.00370.x","article-title":"Biomarkers for cognitive impairment in Parkinson disease","volume":"20","author":"Shi","year":"2010","journal-title":"Brain Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1055\/s-0039-1678579","article-title":"Parkinson\u2019s Disease Dementia and Lewy Body Disease","volume":"39","author":"Sezgin","year":"2019","journal-title":"Semin. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"648982","DOI":"10.3389\/fnagi.2021.648982","article-title":"Fatty Acid-Binding Protein 3 Expression in the Brain and Skin in Human Synucleinopathies","volume":"13","author":"Oizumi","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Kawahata, I., Bousset, L., Melki, R., and Fukunaga, K. (2019). Fatty Acid-Binding Protein 3 is Critical for alpha-Synuclein Uptake and MPP(+)-Induced Mitochondrial Dysfunction in Cultured Dopaminergic Neurons. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215358"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100663","DOI":"10.1016\/j.jbc.2021.100663","article-title":"An alpha-synuclein decoy peptide prevents cytotoxic alpha-synuclein aggregation caused by fatty acid binding protein 3","volume":"296","author":"Fukui","year":"2021","journal-title":"J. Biol. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Yabuki, Y., Matsuo, K., Kawahata, I., Fukui, N., Mizobata, T., Kawata, Y., Owada, Y., Shioda, N., and Fukunaga, K. (2020). Fatty Acid Binding Protein 3 Enhances the Spreading and Toxicity of alpha-Synuclein in Mouse Brain. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062230"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kawahata, I., Sekimori, T., Wang, H., Wang, Y., Sasaoka, T., Bousset, L., Melki, R., Mizobata, T., Kawata, Y., and Fukunaga, K. (2021). Dopamine D2 Long Receptors Are Critical for Caveolae-Mediated alpha-Synuclein Uptake in Cultured Dopaminergic Neurons. Biomedicines, 9.","DOI":"10.3390\/biomedicines9010049"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"147383","DOI":"10.1016\/j.brainres.2021.147383","article-title":"Suppression of alpha-synuclein propagation after intrastriatal injection in FABP3 null mice","volume":"1760","author":"Matsuo","year":"2021","journal-title":"Brain Res."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kawahata, I., and Fukunaga, K. (2020). Degradation of Tyrosine Hydroxylase by the Ubiquitin-Proteasome System in the Pathogenesis of Parkinson\u2019s Disease and Dopa-Responsive Dystonia. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21113779"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"172891","DOI":"10.1016\/j.pbb.2020.172891","article-title":"Novel fatty acid-binding protein 3 ligand inhibits dopaminergic neuronal death and improves motor and cognitive impairments in Parkinson\u2019s disease model mice","volume":"191","author":"Haga","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jphs.2023.02.008","article-title":"Novel FABP3 ligand, HY-11-9, ameliorates neuropathological deficits in MPTP-induced Parkinsonism in mice","volume":"152","author":"Wang","year":"2023","journal-title":"J. Pharmacol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/cns.14120","article-title":"alpha-Synuclein decoy peptide protects mice against alpha-synuclein-induced memory loss","volume":"29","author":"Guo","year":"2023","journal-title":"CNS Neurosci. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"102547","DOI":"10.1016\/j.redox.2022.102547","article-title":"Fatty acid-binding proteins 3 and 5 are involved in the initiation of mitochondrial damage in ischemic neurons","volume":"59","author":"Guo","year":"2023","journal-title":"Redox Biol"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Wang, Y., Shinoda, Y., Cheng, A., Kawahata, I., and Fukunaga, K. (2021). Epidermal Fatty Acid-Binding Protein 5 (FABP5) Involvement in Alpha-Synuclein-Induced Mitochondrial Injury under Oxidative Stress. Biomedicines, 9.","DOI":"10.3390\/biomedicines9020110"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Guo, Q., Kawahata, I., Degawa, T., Ikeda-Matsuo, Y., Sun, M., Han, F., and Fukunaga, K. (2021). Fatty Acid-Binding Proteins Aggravate Cerebral Ischemia-Reperfusion Injury in Mice. Biomedicines, 9.","DOI":"10.3390\/biomedicines9050529"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"103582","DOI":"10.1016\/j.ebiom.2021.103582","article-title":"A novel fatty acid-binding protein 5 and 7 inhibitor ameliorates oligodendrocyte injury in multiple sclerosis mouse models","volume":"72","author":"Cheng","year":"2021","journal-title":"EBioMedicine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41401-021-00675-8","article-title":"Fatty acid-binding protein 7 triggers alpha-synuclein oligomerization in glial cells and oligodendrocytes associated with oxidative stress","volume":"43","author":"Cheng","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1093\/brain\/awad137","article-title":"Epsin2, a novel target for multiple system atrophy therapy via alpha-synuclein\/FABP7 propagation","volume":"146","author":"Cheng","year":"2023","journal-title":"Brain"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jamaneurol.2015.1449","article-title":"Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease","volume":"72","author":"Backstrom","year":"2015","journal-title":"JAMA Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/jnc.14698","article-title":"Clinical and neuropathological differences between Parkinson\u2019s disease, Parkinson\u2019s disease dementia and dementia with Lewy bodies\u2014current issues and future directions","volume":"150","author":"Walker","year":"2019","journal-title":"J. Neurochem."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Jellinger, K.A., and Korczyn, A.D. (2018). Are dementia with Lewy bodies and Parkinson\u2019s disease dementia the same disease?. BMC Med., 16.","DOI":"10.1186\/s12916-018-1016-8"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.expneurol.2008.06.004","article-title":"Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration","volume":"213","author":"Mollenhauer","year":"2008","journal-title":"Exp. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1159\/000105157","article-title":"Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: Marker candidates for dementia with Lewy bodies","volume":"4","author":"Mollenhauer","year":"2007","journal-title":"Neurodegener. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bbrc.2006.08.024","article-title":"Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson\u2019s disease","volume":"349","author":"Tokuda","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.expneurol.2006.12.006","article-title":"Plasma alpha-synuclein is decreased in subjects with Parkinson\u2019s disease","volume":"204","author":"Li","year":"2007","journal-title":"Exp. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10072-019-03738-1","article-title":"Plasma alpha-synuclein levels in patients with Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"40","author":"Bougea","year":"2019","journal-title":"Neurol. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: From overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/jnnp-2016-314857","article-title":"Plasma alpha-synuclein predicts cognitive decline in Parkinson\u2019s disease","volume":"88","author":"Lin","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_29","first-page":"450","article-title":"Parkinson disease: Plasma alpha-synuclein\u2014A potential marker of cognitive impairment in Parkinson disease","volume":"13","author":"Wood","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e044409","DOI":"10.1002\/alz.044409","article-title":"Plasma alpha synuclein (a-syn) as a potential biomarker of diseases with synucleinopathy","volume":"16","author":"Senanarong","year":"2020","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","article-title":"Propagative alpha-synuclein seeds as serum biomarkers for synucleinopathies","volume":"29","author":"Okuzumi","year":"2023","journal-title":"Nat. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatr. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1192\/bjp.140.6.566","article-title":"A new clinical scale for the staging of dementia","volume":"140","author":"Hughes","year":"1982","journal-title":"Br. J. Psychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1258\/000456302760042173","article-title":"Evaluation of a sandwich enzyme-linked immunosorbent assay for the measurement of serum heart fatty acid-binding protein","volume":"39","author":"Pagani","year":"2002","journal-title":"Ann. Clin. Biochem."},{"key":"ref_36","unstructured":"Bland, M. (2015). An Introduction to Medical Statistics, Oxford University Press."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"14129","DOI":"10.1038\/s41598-018-32355-9","article-title":"White matter aberrations and age-related trajectories in patients with schizophrenia and bipolar disorder revealed by diffusion tensor imaging","volume":"8","author":"Kaufmann","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/00224545.1930.9714141","article-title":"Intelligence and Birth Order in Family","volume":"1","author":"Steckel","year":"1930","journal-title":"J. Soc. Psychol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/17\/13267\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:39:47Z","timestamp":1760128787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/17\/13267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,26]]},"references-count":38,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["ijms241713267"],"URL":"https:\/\/doi.org\/10.3390\/ijms241713267","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,26]]}}}